Dr. Clay B. Siegall: The Strategic Plans of Seattle Genetics for the Future

Dr. Clay B. Siegall is a senior researcher, operations management leader, and the head of Seattle Genetics. Dr. Clay sits on the executive board of the company and participates in the development and implementation of the firm’s investment strategies. He is a researcher by training with a robust concentration on targeted cancer therapies. In 1998, Dr. Clay created Seattle Genetics on a strong foundation of revolutionary scientific innovation, exhaustive research, leading drug development practices, and passion for addressing the unique needs of patients.

 

Contributions of Dr. Clay

 

Dr. Clay has steered Seattle Genetics to its current top position in making antibody drug conjugates (ADCs) and in commercializing its first ADC known as ADCETRIS. He has also formed partnerships with the major players in pharmaceutical sectors to market ADCETRIS. For example, Together with Takeda Pharmaceutical Company, Seattle Genetics has transformed ADCETRIS into an international brand approved in over sixty countries.

 

Strategic licenses

 

Dr. Clay has guided Seattle Genetics into securing several strategic licenses for its state-of-the-art ADC technology. The firm’s licenses with AbbVie, Pfizer, Genentech, and GlaxoSmithKline have yielded more than $325 million. Multiple biotechnology companies are using Seattle’s technology to develop several ADCs. The collaborator and in-house programs account for over 20 ADCs, which are in clinical development. Dr. Clay has been in charge of several capital-raising activities on behalf of Seattle Genetics, obtaining over $1.2 billion.

 

Seattle Genetics’ arsenal of antibody-based drugs

 

ADCETRIS is one among the many medications available in the firm’s diverse pipeline of products. According to Dr. Clay, his biotechnology powerhouse has 12 drugs in the clinical trial phase. In 2016, the company introduced an ADC known as 33A into stage three clinical trials. Seattle Genetics is harnessing the power of 33A to treat acute myeloid leukemia. Additionally, the firm is developing a drug for treating breast cancer and two others for managing bladder cancer.

 

Expansion of workforce

 

In 2016, Seattle Genetics embarked on a massive hiring spree. It hired 100 staffs in the United States and around 20 to its Switzerland-headquartered office. Currently, the biotechnology giant has nearly 1,000 employees. Employees hired towards the end of 2016 are in charge of operations of the firm.